68Ga-NOTA-Aca-BBN(7-14) PET imaging of GRPR in children with optic pathway glioma
- 385 Downloads
Optic pathway glioma (OPG) is a rare neoplasm that arises predominantly during childhood. Its location in a sensitive region involving the optic pathways, onset in young patients and controversial therapy choice make the management of OPG a challenge in paediatric neuro-oncology. In this study we assessed gastrin-releasing peptide receptor (GRPR)-targeted positron emission tomography (PET) imaging in children with OPG, and the application of a PET/MRI imaging-guided surgery navigation platform.
Eight children (five boys, mean age 8.81 years, range 5–14 years) with suspicion of optic pathway glioma on MRI were recruited. Written informed consent was obtained from all patients and legal guardians. Brain PET/CT or PET/MRI acquisitions were performed 30 min after intravenous injection of 1.85 MBq/kg body weight of 68Ga-NOTA-Aca-BBN(7-14). Four patients also underwent 18F-FDG brain PET/CT for comparison. All patients underwent surgical resection within 1 week.
All 11 lesions (100%) in the eight patients showed prominent 68Ga-NOTA-Aca-BBN(7-14) uptake with excellent contrast in relation to surrounding normal brain tissue. Tumour-to-background ratios (SUVmax and SUVmean) were significantly higher for 68Ga-NOTA-Aca-BBN(7-14) than for 18F-FDG (28.4 ± 5.59 vs. 0.47 ± 0.11 and 18.3 ± 4.99 vs. 0.35 ± 0.07, respectively). Fusion images for tumour delineation were obtained in all patients using the PET/MRI navigation platform. All lesions were pathologically confirmed as OPGs with positive GRPR expression, and 75% were pilocytic astrocytoma WHO grade I and 25% were diffuse astrocytoma WHO grade II. There was a positive correlation between the SUV of 68Ga-NOTA-Aca-BBN(7-14) and the expression level of GRPR (r2 = 0.56, P < 0.01, for SUVmax; r2 = 0.47, P < 0.05, for SUVmean).
This prospective study showed the feasibility of 68Ga-NOTA-Aca-BBN(7-14) PET in children with OPG for tumour detection and localization. 68Ga-NOTA-Aca-BBN(7-14) PET/MRI may be helpful for assisting surgery planning in OPG patients with severe symptoms, GRPR-targeted PET has the potential to provide imaging guidance for further GRPR-targeted therapy in patients with OPG.
KeywordsOptic pathway glioma (OPG) 68Ga-NOTA-Aca-BBN(7-14) Paediatric neuro-oncology PET PET/MRI Gastrin-releasing peptide receptor (GRPR)
This work was supported in part by the Intramural Research Program (IRP) of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), the National Institutes of Health (NIH), and the National Natural Science Foundation of China (81701742).
Compliance with ethical standards
Conflicts of interest
Statement of human rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study and their legal guardians.
- 7.Sturgess B, Brown M, Fraser F, Bailey S. “They've got a lot of needs and I don't think they're being met fully”: a qualitative study of the multi-professional team approach to the management of children with optic pathway gliomas. Pediatr Blood Cancer. 2018;65:e27377. https://doi.org/10.1002/pbc.27377.CrossRefPubMedGoogle Scholar
- 16.Ananias HJ, Yu Z, Dierckx RA, van der Wiele C, Helfrich W, Wang F, et al. (99m)Technetium-HYNIC(tricine/TPPTS)-Aca-bombesin(7-14) as a targeted imaging agent with microSPECT in a PC-3 prostate cancer xenograft model. Mol Pharm. 2011;8:1165–73. https://doi.org/10.1021/mp200014h.CrossRefPubMedGoogle Scholar
- 18.Heuser M, Schlott T, Schally AV, Kahler E, Schliephake R, Laabs SO, et al. Expression of gastrin releasing peptide receptor in renal cell carcinomas: a potential function for the regulation of neoangiogenesis and microvascular perfusion. J Urol. 2005;173:2154–9. https://doi.org/10.1097/01.ju.0000158135.26893.bc.CrossRefPubMedGoogle Scholar
- 22.Maina T, Bergsma H, Kulkarni HR, Mueller D, Charalambidis D, Krenning EP, et al. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [68Ga]SB3 and PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:964–73. https://doi.org/10.1007/s00259-015-3232-1.CrossRefPubMedGoogle Scholar
- 23.Nock BA, Kaloudi A, Lymperis E, Giarika A, Kulkarni HR, Klette I, et al. Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results. J Nucl Med. 2017;58:75–80. https://doi.org/10.2967/jnumed.116.178889.CrossRefPubMedGoogle Scholar
- 26.Flores DG, Meurer L, Uberti AF, Macedo BR, Lenz G, Brunetto AL, et al. Gastrin-releasing peptide receptor content in human glioma and normal brain. Brain Res Bull. 2010;82:95–8. https://doi.org/10.1016/j.brainresbull.2010.02.014.CrossRefPubMedGoogle Scholar
- 31.Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–20. https://doi.org/10.1007/s00401-016-1545-1.
- 34.Goodden J. Optic pathway hypothalamic glioma. In: Winn HR, editor. Youmans and Winn neurological surgery. 7th ed. Philadelphia: Elsevier; 2016.Google Scholar